Erythropoietin Reduces Post-Pci Arrhythmias in Patients With St-Elevation Myocardial Infarction Publisher Pubmed



Gholamzadeh A¹ ; Amini S² ; Mohammadpour AH³ ; Vahabzadeh M³ ; Fazelifar AF⁴ ; Fazlinezhad A² ; Dehghani M² ; Moohebati M² ; Dastani M² ; Malaekehnikouie B¹ ; Falsoleiman H² Show Affiliations
Source: Journal of Cardiovascular Pharmacology Published:2015

Abstract

Background: Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. Methods: We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with STelevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI. Results: A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI. Conclusion: High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.